Next Article in Journal
A Field Recombinant Strain Derived from Two Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-1) Modified Live Vaccines Shows Increased Viremia and Transmission in SPF Pigs
Next Article in Special Issue
Current State of Compassionate Phage Therapy
Previous Article in Journal
Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses
Previous Article in Special Issue
Protection of Phage Applications in Crop Production: A Patent Landscape
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview

Towards Inhaled Phage Therapy in Western Europe

1
Division of Pulmonary Inflammation, Charité–Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany
2
Department of Infectious Diseases and Respiratory Medicine, Charité–Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany
*
Author to whom correspondence should be addressed.
Viruses 2019, 11(3), 295; https://doi.org/10.3390/v11030295
Received: 15 February 2019 / Revised: 12 March 2019 / Accepted: 20 March 2019 / Published: 23 March 2019
(This article belongs to the Special Issue Hurdles for Phage Therapy (PT) to Become a Reality)
  |  
PDF [253 KB, uploaded 23 March 2019]

Abstract

The emergence of multidrug-resistant bacteria constitutes a great challenge for modern medicine, recognized by leading medical experts and politicians worldwide. Rediscovery and implementation of bacteriophage therapy by Western medicine might be one solution to the problem of increasing antibiotic failure. In some Eastern European countries phage therapy is used for treating infectious diseases. However, while the European Medicines Agency (EMA) advised that the development of bacteriophage-based therapies should be expedited due to its significant potential, EMA emphasized that phages cannot be recommended for approval before efficacy and safety have been proven by appropriately designed preclinical and clinical trials. More evidence-based data is required, particularly in the areas of pharmacokinetics, repeat applications, immunological reactions to the application of phages as well as the interactions and effects on bacterial biofilms and organ-specific environments. In this brief review we summarize advantages and disadvantages of phage therapy and discuss challenges to the establishment of phage therapy as approved treatment for multidrug-resistant bacteria. View Full-Text
Keywords: bacteriophage; phage therapy; multidrug-resistant bacteria; antimicrobial resistance bacteriophage; phage therapy; multidrug-resistant bacteria; antimicrobial resistance
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wienhold, S.-M.; Lienau, J.; Witzenrath, M. Towards Inhaled Phage Therapy in Western Europe. Viruses 2019, 11, 295.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top